Skip Nav Destination
Issues
15 October 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Cancer Research
Table of Contents
Review Articles
Meeting Report
Priority Reports
Association between Large-scale Genomic Homozygosity without Chromosomal Loss and Nonseminomatous Germ Cell Tumor Development
Yong-Jie Lu; Jinshu Yang; Elodie Noel; Spyros Skoulakis; Tracy Chaplin; Manoj Raghavan; Trisha Purkis; Alan Mcintyre; Sakunthala C. Kudahetti; Mahmoud Naase; Dan Berney; Janet Shipley; R. Timothy D. Oliver; Bryan D. Young
Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non–Small Cell Lung Cancers
Nobuhisa Ishikawa; Yataro Daigo; Atsushi Takano; Masaya Taniwaki; Tatsuya Kato; Satoshi Hayama; Haruyasu Murakami; Yukio Takeshima; Kouki Inai; Hitoshi Nishimura; Eiju Tsuchiya; Nobuoki Kohno; Yusuke Nakamura
Molecular Biology, Pathobiology, and Genetics
Continuous MLL-ENL Expression Is Necessary to Establish a “Hox Code” and Maintain Immortalization of Hematopoietic Progenitor Cells
Sarah J. Horton; David G. Grier; Glenda J. McGonigle; Alexander Thompson; Michelle Morrow; Inusha De Silva; Dale A. Moulding; Dimitris Kioussis; Terence R.J. Lappin; Hugh J.M. Brady; Owen Williams
Cell and Tumor Biology
Detection of Early Antiangiogenic Effects in Human Colon Adenocarcinoma Xenografts: In vivo Changes of Tumor Blood Volume in Response to Experimental VEGFR Tyrosine Kinase Inhibitor
Young Ro Kim; Anna Yudina; JoseLuis Figueiredo; Wilfried Reichardt; Dana Hu-Lowe; Alexander Petrovsky; Hye Won Kang; Denise Torres; Umar Mahmood; Ralph Weissleder; Alexei A. Bogdanov, Jr.
Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation
Sacha J. Holland; Mark J. Powell; Christian Franci; Emily W. Chan; Annabelle M. Friera; Robert E. Atchison; John McLaughlin; Susan E. Swift; Erlina S. Pali; George Yam; Stephen Wong; Joe Lasaga; Mary R. Shen; Simon Yu; Weiduan Xu; Yasumichi Hitoshi; Jakob Bogenberger; Jacques E. Nör; Donald G. Payan; James B. Lorens
Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical
Riccardo E. Nisato; Ghamartaj Hosseini; Christian Sirrenberg; Georgina S. Butler; Thomas Crabbe; Andrew J.P. Docherty; Matthias Wiesner; Gillian Murphy; Christopher M. Overall; Simon L. Goodman; Michael S. Pepper
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Tissue Inhibitor of Metalloproteinase-3 Expression from an Oncolytic Adenovirus Inhibits Matrix Metalloproteinase Activity In vivo without Affecting Antitumor Efficacy in Malignant Glioma
Martine L.M. Lamfers; Davide Gianni; Ching-Hsuan Tung; Sander Idema; Frederik H.E. Schagen; Jan E. Carette; Paul H.A. Quax; Victor W. Van Beusechem; W. Peter Vandertop; Clemens M.F. Dirven; E. Antonio Chiocca; Winald R. Gerritsen
Lysophosphatidic Acid Acyltransferase-β Is a Prognostic Marker and Therapeutic Target in Gynecologic Malignancies
Gregory M. Springett; Lynn Bonham; Amanda Hummer; Irina Linkov; Dipika Misra; Chia Ma; Gabriella Pezzoni; Stefano Di Giovine; Jack Singer; Hiroaki Kawasaki; David Spriggs; Robert Soslow; Jakob Dupont
Low-Level Expression of Proapoptotic Bcl-2–Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds
Karl J. Aichberger; Matthias Mayerhofer; Maria-Theresa Krauth; Anja Vales; Rudin Kondo; Sophia Derdak; Winfried F. Pickl; Edgar Selzer; Michael Deininger; Brian J. Druker; Christian Sillaber; Harald Esterbauer; Peter Valent
Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition
Stuart Thomson; Elizabeth Buck; Filippo Petti; Graeme Griffin; Eric Brown; Nishal Ramnarine; Kenneth K. Iwata; Neil Gibson; John D. Haley
Radiosensitivity Enhancement by Celecoxib, a Cyclooxygenase (COX)-2 Selective Inhibitor, via COX-2–Dependent Cell Cycle Regulation on Human Cancer Cells Expressing Differential COX-2 Levels
You Keun Shin; Ji Sun Park; Hyun Seok Kim; Hyun Jung Jun; Gwi Eon Kim; Chang Ok Suh; Yeon Sook Yun; Hongryull Pyo
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
Andries M. Bergman; Paul P. Eijk; Veronique W.T. Ruiz van Haperen; Kees Smid; Gijsbert Veerman; Isabelle Hubeek; Paul van den IJssel; Bauke Ylstra; Godefridus J. Peters
Immunology
Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway
Yulia Nefedova; Srinivas Nagaraj; Amsler Rosenbauer; Carlos Muro-Cacho; Said M. Sebti; Dmitry I. Gabrilovich
Epidemiology and Prevention
Polymorphisms in Cytokine and Cellular Adhesion Molecule Genes and Susceptibility to Hematotoxicity among Workers Exposed to Benzene
Qing Lan; Luoping Zhang; Min Shen; Martyn T. Smith; Guilan Li; Roel Vermeulen; Stephen M. Rappaport; Matthew S. Forrest; Richard B. Hayes; Martha Linet; Mustafa Dosemeci; Blanche P. Alter; Rona S. Weinberg; Songnian Yin; Meredith Yeager; Robert Welch; Suramya Waidyanatha; Sungkyoon Kim; Stephen Chanock; Nathaniel Rothman
Letters to the Editors
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds